Transplantation as disease modifying therapy in the era of gene therapy medicinal products – health policy considerations

Margreet Wagenmakers, Anna Lehman, Caroline den Hoed, Laura van Dussen, Mirjam Langeveld, Sandra Sirrs · 2026

Read Transplantation as disease modifying therapy in the era of gene therapy medicinal products – health policy considerations by Margreet Wagenmakers, Anna Lehman, Caroline den Hoed, Laura van Dussen, Mirjam Langeveld, Sandra Sirrs (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13471253.txt.

Description

A peer-reviewed research article from Europe PMC (2026). BackgroundNew gene therapy medicinal products [GTMP] are being considered as alternatives to liver transplant [LTx] for some patients with inherited metabolic diseases [IMDs] but pose unique challenges for health policy makers.MethodsPublished data on LTx and GTMP in human patients with urea cycle defects [UCD], glycogen storage disease type 1a [GSD1a], methylmalonic aciduria [MMA] and propionic aciduria [PA] were reviewed for efficacy, safety, data quality and health policy considerations.ResultsLTx can reduce [MMA, PA] or eliminate [UCD, GSD1a] metabolic decompensation and improve quality of

Catalog record

CREATORMargreet Wagenmakers, Anna Lehman, Caroline den Hoed, Laura van Dussen, Mirjam Langeveld, Sandra Sirrs
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE47 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13471253

Browse the full library · About the Tower of Babel